Soligenix Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest

Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 66,373 shares, a drop of 59.3% from the October 15th total of 162,935 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average trading volume of 90,729 shares, the days-to-cover ratio is currently 0.7 days.

Soligenix Stock Down 8.7%

SNGX stock traded down $0.03 during trading on Monday, hitting $0.29. The company had a trading volume of 223,761 shares, compared to its average volume of 2,289,809. Soligenix has a 52-week low of $0.28 and a 52-week high of $1.70. The company has a 50 day simple moving average of $0.36 and a 200-day simple moving average of $0.64. The firm has a market capitalization of $6.85 million, a P/E ratio of -0.65 and a beta of 2.04.

Soligenix (NASDAQ:SNGX – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Sell-side analysts forecast that Soligenix will post -0.55 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Get Our Latest Stock Report on Soligenix

About Soligenix

(Get Free Report)

Soligenix, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare diseases and other serious medical conditions. Its work spans therapeutic programs for inflammatory and immunological disorders, as well as vaccine and medical countermeasure development. The company’s BioTherapeutics programs include HyBryte (SGX301), a topical treatment based on synthetic hypericin being developed for cutaneous T-cell lymphoma, and dusquetide (SGX942), which has been studied for oral mucositis associated with cancer treatment.

See Also

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.